Due to the fact that the already published off-target activities of the marketed CysLT1RAs do not sufficiently explain the beneficial effects on cardiovascular outcome and insulin secretion in man as well as their efficacy in various animal models of atherosclerosis and the MetS, we were interested if these compounds interact with sEH and PPAR isoform activities. Here, EPHX2 is linked to metabolic syndrome.